Jon Congleton Sells 15,746 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton sold 15,746 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $13.34, for a total value of $210,051.64. Following the completion of the transaction, the chief executive officer now owns 911,212 shares of the company’s stock, valued at approximately $12,155,568.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jon Congleton also recently made the following trade(s):

• On Friday, June 14th, Jon Congleton sold 16,229 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $12.52, for a total value of $203,187.08.
• On Wednesday, June 12th, Jon Congleton sold 16,607 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $212,071.39.

Mineralys Therapeutics Price Performance

Shares of MLYS stock opened at $14.48 on Friday. The company’s fifty day moving average price is $12.74 and its two-hundred day moving average price is $12.35. The firm has a market capitalization of $718.93 million, a P/E ratio of -6.61 and a beta of 1.97. Mineralys Therapeutics, Inc. has a 12 month low of $5.85 and a 12 month high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.02). On average, sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -2.92 EPS for the current year.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Mineralys Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,931 shares of the company’s stock valued at $102,000 after acquiring an additional 3,181 shares in the last quarter. CWM LLC boosted its stake in Mineralys Therapeutics by 120.0% during the fourth quarter. CWM LLC now owns 5,891 shares of the company’s stock valued at $51,000 after buying an additional 3,213 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Mineralys Therapeutics by 17,821.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock worth $35,000 after acquiring an additional 4,099 shares during the period. Vanguard Group Inc. raised its position in Mineralys Therapeutics by 0.5% in the first quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock worth $12,690,000 after acquiring an additional 4,952 shares in the last quarter. Finally, Bellevue Group AG acquired a new stake in Mineralys Therapeutics in the 1st quarter valued at about $119,000. Institutional investors own 84.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MLYS shares. Lifesci Capital reaffirmed an “outperform” rating on shares of Mineralys Therapeutics in a research note on Tuesday, March 26th. HC Wainwright began coverage on Mineralys Therapeutics in a research report on Wednesday. They set a “buy” rating and a $30.00 price target for the company. Finally, The Goldman Sachs Group began coverage on Mineralys Therapeutics in a report on Tuesday, April 2nd. They issued a “buy” rating and a $30.00 price target for the company.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.